Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis
ConclusionOur study reports for the first time a high incidence (48.1%) of intramyocardial inflammation in a series of patients with EMB‐proven cardiac amyloidosis and could show that in patients with AL amyloidosis, intramyocardial inflammation correlated significantly with increased mortality. Our data have a direct clinical impact because one can hypothesize that additional immunomodulating/anti‐inflammatory treatment regimens in patients with biopsy‐proven inflammation of heart muscle tissue could be beneficial for patients suffering from cardiac AL amyloidosis.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Christine S. Siegismund, Felicitas Escher, Dirk Lassner, Uwe K ühl, Ulrich Gross, Friedrich Fruhwald, Philip Wenzel, Thomas Münzel, Norbert Frey, Reinhold P. Linke, Heinz‐Peter Schultheiss Tags: Research Article Source Type: research